Skip to main content
SpringerLink
Log in

Schwerpunkt Supportivmedizin

Management von Nebenwirkungen bei bispezifischen Antikörpern und CAR-T-Zellen

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Li R et al. The CAR T-Cell Mechanoimmunology at a Glance. Adv Sci (Weinh). 2020;7(24):2002628

  2. Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019;37 Suppl 1:48-52

  3. Giavridis T et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731-8

  4. Obstfeld AE et al. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. Blood. 2017;130(23):2569-72

  5. Neelapu SS et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531-44

  6. Schubert ML et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34-48

  7. Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 2021;56(3):552-66

  8. Strati P et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020;4(13):3123-7

  9. Patel S et al. Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab. Blood. 2022;140(Suppl_1):5073-4

  10. Maude SL et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-48

  11. Locke FL et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640-54

  12. Hill JA et al. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev. 2019;38:100596

  13. Kantarjian H et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836-47

  14. Moreau P et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495-505

  15. Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-65

  16. Schubert ML et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34-48

Download references

Author information

Authors and Affiliations

  1. Onkozentrum Zürich, Seefeldstrasse 214, 8008, Zürich, Schweiz

    Ulf Petrausch

Authors
  1. Ulf Petrausch
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petrausch, U. Management von Nebenwirkungen bei bispezifischen Antikörpern und CAR-T-Zellen. InFo Hämatol Onkol 26, 26–29 (2023). https://doi.org/10.1007/s15004-023-9895-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-023-9895-z

Search

Navigation